Vericel

Vericel Corporation is a publicly traded advanced cell therapy company (NASDAQ: VCEL) focused on the sports medicine and severe burn care markets in the United States. The company manufactures and markets MACI (autologous cultured chondrocytes on porcine collagen membrane) for repair of cartilage defects of the knee, Epicel (cultured epidermal autografts) for the treatment of severely burned patients, and holds an exclusive North American license for NexoBrid, a biological orphan product approved for eschar removal in severe thermal burns. Vericel is committed to improving the lives of patients with serious conditions through innovative cell therapies and specialty biologics, combining advances in cell biology with specialized manufacturing.